ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1977

Impact of Ultrasound in Treatment Decision of Rheumatoid Arthritis Assessed in Routine Clinical Practice

César Sifuentes-Cantú1, Lina Saldarriaga-Rivera2, Ana Cecilia Lozada2, Irazu Contreras-Yañez3, Marwin Gutierrez4 and Virginia Pascual-Ramos5, 1Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, 2Division of musculoskeletal and rheumatic diseases, Instituto Nacional de Rehabilitación, Mexico City, Mexico, 3Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico, Mexico, 4Instituto Nacional de Rehabilitación, Mexico, Mexico, 5Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: treatment and ultrasound

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 14, 2016

Title: Imaging of Rheumatic Diseases II: Ultrasound in Rheumatoid Arthritis

Session Type: ACR Concurrent Abstract Session

Session Time: 2:30PM-4:00PM

Background/Purpose: Remission or low disease activity is the therapeutic target for rheumatoid arthritis (RA). There is a consistent body of evidence supporting the value of ultrasound in the diagnosis, disease activity and treatment monitoring of RA patients. In spite of these pieces of information, the impact of ultrasound in treatment decisions in RA patients from real clinical setting has not yet sufficiently studied. Purpose: To explore the impact of ultrasound findings, in terms of the proportion of patients in whom treatment recommendation differed after the ultrasound examination in RA outpatients. We also tested the variations of ultrasound impact according to the level of patient´s disease activity or the physician´s experience.

Methods: 85 consecutive RA outpatients were included. In the 1st step a senior rheumatologist (SR) and a trainee in rheumatology (TR), blinded to each other evaluation performed a clinical assesment that included DAS28; then, they independently proposed a treatment recommendation. In a 2nd step, all patients underwent an ultrasound examination using the 7-joints score (US-7,[2]) by an experienced rheumatologist blinded to clinical evaluation; US-7 assessed gray scale sinovitis (GS), power doppler sinovitis (PD) and accordingly determined disease activity. In the final step, all the patients returned to both, the SR and the TR, who integrated the US-7 findings to their previous evaluation and reviewed their prescription. TR and SR changes of treatment (pre- and post-US-7) were recorded on standardized formats. Patients received final recommendation only from the SR. US-7 usefulness was separately evaluated by the SR and the TR according to a Likert scale (0= not useful at all, 10= very useful). Patients signed informed consent.

Results: Patients were mainly female (91.4%), with (mean±SD) 45.13 ± 12.4 years of age and disease duration of 7.45±3.9 years. Sixty one (71.8%) patients were in DAS28-remission (<2.6), meanwhile 24 (28.2%) had some level of disease activity according to DAS28. US-7 evaluations showed that 98.8% of the patients had at least some degree of GS sinovitis and 22.6% had PD. In 34 (20%) out of the 170 clinical evaluations (85 patients concomitantly evaluated by SR and TR), US-7 modified treatment and it was most frequently increased. Interestingly, 24 out of these 34 evaluations were performed by TR vs. 10 performed by the SR: 70.5% vs. 29.5%, p=0.01. Also, US-7 usefulness was scored higher by TR than by the SR, 4.9±2.5 mm vs. 4.1±1.8, p= 0.02. Disease activity did not affect the impact of US-7 on treatment recomendation.

Conclusion: US-7 findings impacted treatment in up to 20% of RA patients assessed in routine clinical practice; this impact was greater in TR than in SR. References: 1. Naredo E, Collado P, Cruz A, Palop MJ, et al. Longitudinal power Doppler ultrasonographic assessment of joint inflammatory activity in early rheumatoid arthritis: predictive value in disease activity and radiologic progression. Arthritis Rheum. 2007 Feb 15;57(1):116-24. 2. Backhaus et al. Evaluation of a novel 7-joint ultrasound score in daily rheumatologic practice: a pilot project. Arthritis Rheum. 2009;61: 1194-201


Disclosure: C. Sifuentes-Cantú, None; L. Saldarriaga-Rivera, None; A. C. Lozada, None; I. Contreras-Yañez, None; M. Gutierrez, None; V. Pascual-Ramos, None.

To cite this abstract in AMA style:

Sifuentes-Cantú C, Saldarriaga-Rivera L, Lozada AC, Contreras-Yañez I, Gutierrez M, Pascual-Ramos V. Impact of Ultrasound in Treatment Decision of Rheumatoid Arthritis Assessed in Routine Clinical Practice [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/impact-of-ultrasound-in-treatment-decision-of-rheumatoid-arthritis-assessed-in-routine-clinical-practice/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/impact-of-ultrasound-in-treatment-decision-of-rheumatoid-arthritis-assessed-in-routine-clinical-practice/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology